

Kwality Pharmaceuticals Africa Limitada

Mozambique, Maputo Province, City Of Matola

Balance Sheet As On 31st March, 2024

	Particulars	Figures as at the end of 31/03/2024 (in Rs.)
A	EQUITY AND LIABILITIES	
1	Shareholders' funds	
	(a) Share capital	8,867,500.00
	(b) Reserves and surplus	-33,635,804.98
	(b) Money Received against share warrents	-
2	Share application money pending allotments	-
3	Non-current liabilities	
	(a) Long-term borrowings	26,630,921.58
	(b) Deferred tax liabilities (net)	-
	(c) Other Long Term Liabilities	-
	(d) Long term provision	-
4	Current liabilities	
	(a) Short Term Borrowings	-
	(b) Trade payables	
	(A) total outstanding dues of micro enterprises and small enterprises	-
	(B) total outstanding dues of Creditors other than micro enterprises and small enterprises	15,941,972.79
	(c) Other current liabilities	-
	(d) Short-term provisions	-
	TOTAL	17,804,589.39
B	ASSETS	
1	Non-current assets	
	(a) (i) Property, Plant and Equipment	8,744,371.44
	(ii) Intangible assets	-
	(iii) Capital Work in progress	-
	(iv) Intangible Assets under Development	
	(b) Non-current investments	
	(c) Deferred Tax Assets	-
	(d) Long term loans and Advances	
	(e) Other Non Current Assets	
2	Current assets	
	(a) Current Investments	-
	(b) Inventories	-
	(c) Trade receivables	-
	(d) Cash and cash equivalents	9,060,217.94
	(e) Short-term loans and advances	-
	(f) Other Current Assets	-
	TOTAL	17,804,589.38

For Kwality Pharmaceuticals Africa Limitada

Sd/-
Ramesh Arora
Director

Sd/-
Rajendra Singh Golan
Director

Kwality Pharmaceuticals Africa Limitada

Mozambique, Maputo Province, City Of Matola

STATEMENT OF PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31st MARCH 2024

	Particulars	Figures for the year ended 31/03/2024 (in Rs.)
I	Revenue from operations	-
II	Other Income	-
III	Total Income (I+II)	-
IV	Expenses	
	(a) Cost of materials consumed	-
	(b) Purchase of Stock in Trade	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-
	(d) Employee benefits expenses	371,163.28
	(e) Finance costs	-
	(f) Depreciation and amortisation expenses	481,230.46
	(g) Other expenses	2,828,152.15
	Total Expenses	3,680,545.89
V	Profit before exceptional and extraordinary item and tax	(3,680,545.89)
VI	Exceptional Items	-
VII	Profit before extraordinary item and tax	(3,680,545.89)
VIII	Extraordinary Items	-
IX	Profit before Tax	(3,680,545.89)
X	Tax Expense:	
	(a) Current tax expense	-
	(b) Deferred tax	-
	(c) Income tax relating to previous year	-
XI	Profit / (Loss) for the period from continuing operations	(3,680,545.89)
XII	Profit / (Loss) from discontinuing operations	
XIII	Tax from discontinuing operations	-
XIV	Profit/ (Loss) from discontinuing operations	-
XV	Profit/ (Loss) for the Period	(3,680,545.89)

For Kwality Pharmaceuticals Africa Limitada

Sd/-
Ramesh Arora
DirectorSd/-
Rajendra Singh Golan
Director